source
- Crystalys mines $130M series B to push gout drug through phase 3Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.
- Tempus acquires Personalis for $1.5 billion to expand cancer genomics and MRD testingTempus announced it will purchase Personalis in a transaction valued at $1.5 billion, giving it full ownership of the cancer‑genomics firm. The deal builds on a 2023 partnership where Tempus inves…